Literature DB >> 24159572

Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail?

M Kudo.   

Abstract

Entities:  

Year:  2012        PMID： 24159572      PMCID： PMC3747550          DOI： 10.1159/000342401

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  7 in total

1.  Effect of vitamin K2 on the recurrence of hepatocellular carcinoma.

Authors:  Haruhiko Yoshida; Yasushi Shiratori; Masatoshi Kudo; Shuichiro Shiina; Toshihiko Mizuta; Masamichi Kojiro; Kyosuke Yamamoto; Yukihiro Koike; Kenichi Saito; Nozomu Koyanagi; Takao Kawabe; Seiji Kawazoe; Haruhiko Kobashi; Hiroshi Kasugai; Yukio Osaki; Yasuyuki Araki; Namiki Izumi; Hiroko Oka; Kunihiko Tsuji; Joji Toyota; Toshihito Seki; Toshiya Osawa; Naohiko Masaki; Masao Ichinose; Masataka Seike; Akihisa Ishikawa; Yoshiyuki Ueno; Kazumi Tagawa; Ryoko Kuromatsu; Shotaro Sakisaka; Hiroshi Ikeda; Hidekatsu Kuroda; Hiroyuki Kokuryu; Tatsuya Yamashita; Isao Sakaida; Tetsuo Katamoto; Kentaro Kikuchi; Minoru Nomoto; Masao Omata
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

2.  Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

Authors:  Masatoshi Kudo; Kazuho Imanaka; Nobuyuki Chida; Kohei Nakachi; Won-Young Tak; Tadatoshi Takayama; Jung-Hwan Yoon; Takeshi Hori; Hiromitsu Kumada; Norio Hayashi; Shuichi Kaneko; Hirohito Tsubouchi; Dong Jin Suh; Junji Furuse; Takuji Okusaka; Katsuaki Tanaka; Osamu Matsui; Michihiko Wada; Iku Yamaguchi; Toshio Ohya; Gerold Meinhardt; Kiwamu Okita
Journal:  Eur J Cancer       Date:  2011-09       Impact factor: 9.162

Review 3.  Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 4.  Chemoembolization in patients with hepatocellular carcinoma.

Authors:  Riccardo Lencioni
Journal:  Liver Cancer       Date:  2012-06       Impact factor: 11.740

5.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

6.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
  7 in total
  5 in total

1.  Lenvatinib in Advanced Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-08-29       Impact factor: 11.740

2.  Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-02-15       Impact factor: 11.740

Review 3.  Alteration of Epigenetic Profile in Human Hepatocellular Carcinoma and Its Clinical Implications.

Authors:  Naoshi Nishida; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

4.  Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study.

Authors:  Andrea Casadei Gardini; Flavia Foca; Mario Scartozzi; Nicola Silvestris; Emiliano Tamburini; Luca Faloppi; Oronzo Brunetti; Britt Rudnas; Salvatore Pisconti; Martina Valgiusti; Giorgia Marisi; Francesco Giuseppe Foschi; Giorgio Ercolani; Davide Tassinari; Stefano Cascinu; Giovanni Luca Frassineti
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

Review 5.  Drug therapy for advanced-stage liver cancer.

Authors:  Markus Peck-Radosavljevic
Journal:  Liver Cancer       Date:  2014-05       Impact factor: 11.740
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.